Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoLEEta adjuvant chemotherapy de-escalation trial with ribociclib in HR-positive HER2-negative early breast cancer
NL-OMON60071Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribociclib and anastrozole in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Invasive breast cancer-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ribociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60071.